Inventaire - your friends and communities are your best library

Optimizing renal function and outcome of patients with cT2 renal cell carcinoma

লেখক

Luca Faloppi

Vincenzo Di Nunno

F Massari

এতে প্রকাশিত: Annals of Translational Medicine

তারিখে প্রকাশিত: 2019-03-01

ভাষা: ইংরেজি ভাষা

মূল বিষয়: renal cell carcinoma

Cites articles 17

তারিখ

শিরোনাম

লেখকগণ

2019-01-11

Use of Physiologically Based Pharmacokinetic Modeling to Identify Physiological and Molecular Characteristics Driving Variability in Axitinib Exposure: A Fresh Approach to Precision Dosing in Oncology

Michael J. Sorich, Ashley M. Hopkins
2018-06-05

Immunotherapy in renal cell carcinoma: latest evidence and clinical implications

F Massari, Vincenzo Di Nunno, Alessandro Conti, Alessia Cimadamore, Marina Scarpelli, Antonio Lopez-Beltran, Rodolfo Montironi, Matteo Santoni, Nicola Battelli
2018-11-20

Evaluation of axitinib to downstage cT2a renal tumours and allow partial nephrectomy: a phase II study

Cedric Lebacle, Jean-Christophe Bernhard, Laurence Albiges
2017-05-04

Renal Mass and Localized Renal Cancer: AUA Guideline

Eric Bass, Anthony Chang, Jeffrey A Cadeddu
2016-12-01

Axitinib induces senescence-associated cell death and necrosis in glioma cell lines: The proteasome inhibitor, bortezomib, potentiates axitinib-induced cytotoxicity in a p21(Waf/Cip1) dependent manner

Angela Santoni
2015-01-01

Morphologic and molecular backgrounds for personalized management of genito-urinary cancers: an overview

Matteo Santoni, Antonio Lopez-Beltran, Marina Scarpelli, Rodolfo Montironi, Holger Moch
2015-01-01

Morphological and molecular backgrounds for personalized therapies in genitourinary cancers.

Rodolfo Montironi, Marina Scarpelli, Liang Cheng, Antonio Lopez-Beltran, Matteo Santoni
2015-01-01

Present and future of personalized medicine in adult genitourinary tumors

Alessandro Conti, Matteo Santoni, Giampaolo Tortora, Stefano Cascinu, Rodolfo Montironi, Marina Scarpelli, Liang Cheng, Antonio Lopez-Beltran, Chiara Ciccarese
2015-05-13

Small renal masses in the era of personalized medicine: Tumor heterogeneity, growth kinetics, and risk of metastasis

Alessandro Conti, Matteo Santoni, Stefano Cascinu, Lars Lund, Marina Scarpelli, Antonio Lopez-Beltran, Rodolfo Montironi, Giovanni Muzzonigro, Luciano Burattini, Valeria Sotte
2015-07-01

The immunocheckpoints in modern oncology: the next 15 years

Daniele Santini, F Massari, Matteo Santoni, Chiara Ciccarese
2015-07-11

BAP1, PBRM1 and SETD2 in clear-cell renal cell carcinoma: molecular diagnostics and possible targets for personalized therapies

Francesco Piva, Matteo Santoni, Matteo Giulietti, F Massari, Antonio Lopez-Beltran, Giovanni Principato, Stefano Cascinu, Marina Scarpelli, Rodolfo Montironi, Marc R Matrana, Giulia Occhipinti
2015-09-25

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

Bernard Escudier, Frede Donskov, John Wagstaff, Giuseppe Procopio, Alain Ravaud, Howard Gurney, Robert Motzer, Toni K Choueiri
2015-11-01

Axitinib induces DNA damage response leading to senescence, mitotic catastrophe, and increased NK cell recognition in human renal carcinoma cells

Maria Beatrice Morelli, Alessandra Soriani, Claudio Cardinali, Angela Santoni
2013-07-02

Renal function after nephron-sparing surgery versus radical nephrectomy: results from EORTC randomized trial 30904.
2010-01-18

Outcome of stage T2 or greater renal cell cancer treated with partial nephrectomy

Rodney H Breau
2010-10-16

Primary tumor response to targeted agents in patients with metastatic renal cell carcinoma
2007-10-23

Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study

Robert Motzer, George Wilding, Olivier Rixe

নিবন্ধ - wd:Q64073950

জায়ে আপনাকে স্বাগত

the library of your friends and communities

আরো জানুন